Targeting proteostasis of the HEV replicase to combat infection in preclinical models
Fei Zhang,Ling-Dong Xu,Qian Zhang,Ailian Wang,Xinyuan Yu,Shengduo Liu,Chu Chen,Shiying Wu,Jianping Jin,Aifu Lin,Dante Neculai,Bin Zhao,Xin-Hua Feng,Tingbo Liang,Pinglong Xu,Yao-Wei Huang
DOI: https://doi.org/10.1016/j.jhep.2022.12.010
IF: 25.7
2022-12-26
Journal of Hepatology
Abstract:Background & Aims Hepatitis E virus (HEV) is a globally prevalent pathogen, annually resulting in 20 million infections, 3 million cases of clinical disease, and 60,000 fatalities worldwide, significantly endangering pregnant women and immunocompromised individuals. HEV-related research has been considerably delayed, and no HEV-specific therapeutics have yet been developed. We aimed to discover efficient anti-HEV drugs through high throughput screening that could be validated in vitro and in a preclinical animal study in vivo, and elucidate the underlying antiviral mechanism. Methods Using appropriate cellular and rodent HEV infection models, we studied a critical pathway for host-HEV interaction and performed a preclinical study of the corresponding antivirals by targeting proteostasis of the HEV replicase. Results We found 17 inhibitors that target HEV-HSP90 interactions by an unbiased compound library screening on human hepatocytes harboring an HEV replicon. Inhibitors of HSP90 (iHSP90) markedly suppressed HEV replication with efficacy exceeding that of conventional antivirals (IFNα and ribavirin) in vitro. Mechanistically, iHSP90 treatment released the viral replicase ORF1 protein from the ORF1-HSP90 complex and triggered ORF1 for rapid ubiquitin/proteasome-mediated degradation, resulting in abrogated HEV replication. Furthermore, a preclinical trial in a Mongolian gerbil HEV infection model showed this novel anti-HEV strategy to be safe, efficient, and able to prevent HEV-induced liver damage. Conclusions This study collectively illustrates a critical proteostasis pathway for host-HEV interaction and paves the way for translating the new understanding of the HEV life cycle into clinically promising antivirals. Impact and implications Appropriate treatment options for HEV-infected pregnant women as well as immunocompromised patients are lacking, creating an urgent need for developing safe HEV-specific therapies. This study identified new antivirals (inhibitors of HSP90) that significantly decrease the HEV infection by targeting viral replicase for degradation. Moreover, these anti-HEV drugs were validated in an HEV rodent model and found to be safe and efficient for prevention of HEV-induced liver injury in preclinical experiments. Our findings substantially promote the understanding of HEV pathobiology and the pace of antiviral development.
gastroenterology & hepatology